In prior studies, modulation of fructose transporter GLUT5 (SLC2A5) was found to have potential for treating metabolic disease, since GLUT5 is involved in fructose metabolism and intestinal fructose absorption [6]. This evidence concerns the gene SLC2A5 and metabolic disease.